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Abstract. In the current project we focused on the synthesis of 4-Substituted-2-p-tolylthiazole derivatives. 
Cytotoxicity of synthesized compounds were evaluated against T47D breast cancer cell line and also all of 
the final compounds 3−7 were docked into the active site of c-Src and erb tyrosine kinases. Compound 4 
was the most potent derivative in cytotoxicity assay (IC50 = 2.5 µg/mL) and it was also the most potent in-
hibitor of erb tyrosine kinase (Binding free energy: −10.18 kcal/mol).(doi: 10.5562/cca1939) 
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INTRODUCTION 
Breast cancer is the leading type of cancer in women 
and is the second leading cause of cancer death among 
women. Breast cancer also occurs in men, although far 
more rarely than in women.1 
Despite the past efforts to develop selective target-
ed therapies for the treatment of cancer, the aim has 
recently turned to find compounds acting on multiple 
targets in order to face the drug resistance often con-
nected to the activation of alternative signaling path-
ways. Protein tyrosine kinases occupy a central position 
in the control of cellular proliferation and their inactiva-
tion might lead to the discovery of a new generation 
anticancer compounds. Multikinase inhibitors currently 
approved for cancer chemotherapy include lapatinib, 
sorafenib and dasatinib (Figure 1). These agents are 
effective in treatment of solid tumors such as breast 
cancer.2–4 
c-Src kinase, is the best understood member of a 
family of related kinases known as the SFKs (Src family 
kinases). c-Src plays a major role in multiple intracellu-
lar signaling pathways involved in cell growth, differen-
tiation, survival, adhesion, and migration. It has been 
demonstrated that Src is overexpressed or constitutively 
active in a variety of human tumors like breast cancer.5,6 
The erbB receptors are a family of Type 1 
transmembrane receptors that express highly in human 
tumors. erbB receptors are activated by various growth 
factor ligands triggering intracellular signalling path-
ways leading to uncontrolled growth of cancer cells like 
breast cancer. Lapatinib is an oral 4-anilinoquinazoline 
derivative that inhibits reversibly tyrosine kinase of 
HER1, HER2/ErbB2 and EGFR (dual tyrosine kinase 
inhibitor).7,8 
In this project we synthesized some new deriva-
tives of 4-Substituted-2-p-tolylthiazole. Docking studies 
of synthesized compounds into the active site of two 
types of tyrosine kinases consist of c-Src and erb could 
suggest the inhibition of these enzymes as probable 
mechanism for anticancer activity of these compounds 




All starter materials, reagents and solvents were pur-
chased from diverse commercial companies. The purity 
of the synthesized compounds was confirmed by thin 
layer chromatography (TLC) using various solvents of 
different polarities. Merck silica gel 60F254 plates were 
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applied for analytical TLC. Column chromatography 
was performed on Merck silica gel (70−230 mesh) for 
purification of intermediate and final compounds. 1H 
NMR spectra were measured using a Varian 400 spec-
trometer, and chemical shifts are expressed as δ (ppm) 
with tetramethylsilane (TMS) as internal standard. The 
IR spectra were obtained on a Shimadzu 470 spectro-
photometer (potassium bromide disks). Melting points 
were determined on a Kofler hot stage apparatus and are 
uncorrected. The mass spectra were run on a Finigan 
TSQ-70 spectrometer (Finigan, USA) at 70 eV. 
The intended compounds were synthesized ac-
cording to the Scheme 1. 
 
Synthesis of 4-Methylbenzothioamide (2) 
A solution of compound 1 (4g, 35 mmol) and ammoni-
um sulfide 20% (11.67 ml, 35 mmol) was stirred in 50 
ml of N,N-dimethylformamide (DMF) for about 5 h at 
room temperature. Cooling the reaction by crushed ice 
led to the precipitation of compound 2.9 Extra purifica-
tion was done by washing the solid using n-hexane. The 
obtained product was used for the next reaction without 
any extra purification. m.p. = 160 °C; Yield: 92 %, 1H 
Figure 1. Chemical Structures of dasatinib and lapatinib as multikinase inhibitors. 
 
Scheme 1. Synthesis of compounds 2−7. a) Ammonium sulfide, DMF, rt, 5 h; b) Toluene, Reflux, 2 h; c) H2SO4, H2O, Reflux,
24–48 h; d) MnO2, CHCl3, rt, 10 h; e) H2O2 30 %, KOH, CH3OH, f) EDC, HOBt, CH3CN, piperidine, rt, 24 h. 
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NMR (400 MHz, CDCl3) δ/ppm: 2.39 (s, 3H, -CH3), 
7.21 (d, 2H, J = 8 Hz, phenyl), 7.79 (d, 2H, J= 8 Hz, 
phenyl), 7.6 (brs, NH2). Elem. anal. for C8H9NS: calcd. 
C: 63.54, H: 6.00, N: 9.26; found C: 63.59, H: 6.17, N: 
9.22. 
 
Synthesis of 4-(Chloromethyl)-2-p-tolylthiazole (3) 
A mixture of 2 (3.5g, 23 mmol) and 1,3-dichloroacetone 
(2.9 g, 23 mmol) were dissolved in 100 ml toluene and 
the reaction was refluxed for 2 hours. After completion, 
toluene was evaporated under reduced pressure and 
water was added. The water layer was extracted three 
times by 50 ml of ethylacetate. The ethylacetate was 
washed two times by brine and was dried using dry 
NaSO4. The ethylacetate was evaporated by rotary 
evaporator apparatus and afforded precipitate was re-
crystallization from methanol.10 m.p. = 129 °C; Yield: 
88 %; 1H NMR (400 MHz, CDCl3) δ/ppm: 2.39 (s, 3H, 
CH3), 4.74 (s, 2H, -CH2Cl), 7.25 (s, 1H, C4-H thiazole), 
7.23 (d, 2H, J= 8 Hz, C3-H, C5-H phenyl), 7.82 (d, 2H, 
J = 8 Hz); IR (KBr) v/cm−1: 3431, 3083 (C−H stretch, 
aromatic), 2847 (C−H stretch, aliphatic), 1603 (C=C 
stretch, phenyl), 1460 (C=C stretch, phenyl), 1255, 
1152, 999, 809 (C−Cl stretch), 650; MS (m/z, %): 223 
(20), 220 (42), 186 (40), 116 (55), 87 (38), 69 (100). 
Elem. anal. for C11H10ClNS: calcd. C: 59.05, H: 4.51, 
N: 6.26; found C: 59.11, H: 4.49, N: 6.31. 
 
Synthesis of (2-p-tolylthiazol-4-yl)methanol (4) 
The 4-(Chloromethyl)-2-p-tolylthiazole derivative (4.5 
g, 22 mmol) (3) was dissolved in 75 ml water and 75 ml 
concentrated H2SO4. The reaction was refluxed for 24–
48 hours and the completion was monitored by TLC. 
The acidic reaction was neutralized by concentrated 
NaOH and remain overnight at room temperature to 
precipitate the product. Purification of the obtained 
product was done by crystallization from chloroform-
petroleum ether.10 m.p. = 114–115 °C; Yield: 75 %; 1H 
NMR (400 MHz, CDCl3) δ/ppm: 2.4 (s, 3H, CH3), 3.1 
(brs, 1H, OH), 4.8 (s, 2H, CH2), 7.2 (d, 2H, J = 8 Hz, 
C3-H, C5-H phenyl), 7.27 (s, 1H, C4-H thiazole), 7.82 
(d, 2H, J= 8 Hz, C2-H C6-H phenyl); IR (KBr) v/cm
−1: 
3436, 2929 (C−H stretch, aliphatic), 1649, 1454 (C=C 
stretch, phenyl), 1152 (C−O, stretch), 1029, 804, 599. 
Elem. anal. for C11H11NOS: Calc. C: 64.36, H: 5.40, N: 
6.82; found C: 64.41, H: 5.36, N: 6.85. 
 
Synthesis of 2-p-tolylthiazole-4-carbaldehyde (5) 
A mixture of (2-p-tolylthiazol-4-yl)methanol derivative 
(4) (2.8 g, 13 mmol) and MnO2 (9.04 g, 104 mmol) 
were added to the 250 ml of chloroform and was stirred 
at room temperature for 12 hours. Then, chloroform was 
evaporated under reduced pressure and diethyl ether 
(Et2O) was added. The mixture was filtered through a 
packed layer of diatomatous earth and was washed by 
diethyl ether. Diethyl ether was evaporated under re-
duced pressure and the product was crystallized from 
ethanol.10 m.p. = 128−130 °C; Yield: 70 %; 1H NMR 
(400 MHz, CDCl3) δ/ppm: 2.4 (s, 3H, CH3), 7.25 (d, 
2H, J= 8 Hz, C3-H, C5-H phenyl), 7.84 (d, 2H, J = 8 Hz, 
C2-H C6-H phenyl), 8.1 (s, 1H, C4-H thiazole), 10.1 (s, 
C-H aldehyde); MS (m/z, %): 204 (15), 201 (100), 173 
(30), 140 (58), 115 (68), 89 (40), 84 (65), 58 (85). Elem. 
anal. for C11H9NOS: calcd. C: 65.00, H: 4.46, N: 6.89; 
found C: 64.93, H: 5.53, N: 6.83. 
 
Synthesis of 2-p-tolylthiazole-4-carboxylic acid (6) 
Hydrogen peroxide 30 % (4ml, 40 mmol) was added 
dropwise to the 2-p-tolylthiazole-4-carbaldehyde (5) 
(1g, 5 mmol) and 50 % aqueous KOH (1.47 ml, 20 
mmol) in methanol under reflux condition (65 °C) for 
about 20 minutes and reflux conditions was continued 
for 10 minutes. The mixture was cooled and acidified 
with concentrated hydrochloric acid.11 m.p. = 123 °C; 
Yield: 82 %; 1H NMR (400 MHz, CDCl3) δ/ppm: 2.4 (s, 
3H, CH3), 7.25 (d, 2H, J = 8 Hz, C3-H, C5-H phenyl), 
7.9 (d, 2H, J= 8 Hz, C2-H, C6-H phenyl), 8.14 (s, 1H, 
C4-H thiazole). IR (KBr) v/cm−1: 3277 (OH stretch), 
3078 (C−H stretch, aromatic), 2919 (C−H stretch, ali-
phatic), 2858 (C−H stretch, aliphatic), 1721 (C=O 
stretch), 1603 (C=C stretch, phenyl), 1521, 1454 (C=C 
stretch, phenyl), 1403, 1342, 1244 (C−O stretch), 809; 
MS (m/z, %): 221 (10), 219 (100), 175 (22), 134 (30), 
119 (95), 115 (75), 91 (40), 56 (32). Elem. anal. for 
C11H9NO2S: calcd. C: 60.26, H: 4.14, N: 6.39; found C: 




Carboxylic acid derivative 6 (1 g, 4 mmol), EDC (0.8 
g, 4 mmol) and hydroxybenzotriazole (HOBt) (0.5 g, 4 
mmol) were stirred in acetonitrile at room temperature 
for 30 minutes. Then, piperidine (0.38 g, 0.45 ml, 16 
mmol) was added to the reaction mixture and stirring 
was continued for 24 h. Acetonitrile was evaporated 
under reduced pressure and ethyl acetate was added to 
the residue. Ethyl acetate was washed with diluted 
sulfuric acid (H2SO4), sodium bicarbonate (NaHCO3) 
and brine. Ethyl acetate phase was separated and an-
hydrous sodium sulfate (Na2SO4) was added for dry-
ing. Evaporation of ethyl acetate yielded the related 
amide derivative 7. Diethyl ether was added for wash-
ing the product and the solid was filtered. m.p. = 78 
°C; Yield: 70 %; 1H NMR (400 MHz, CDCl3) δ/ppm: 
1.7 (m, 2H, -CH2- piperidine), 2.37 (m, -CH2-, 
piperidine), 2.4 (s, 3H, -CH3), 3.77 (m, -N-CH2-, 
piperidine), 7.22 (d, 2H, J = 8 Hz, C3-H, C5-H phenyl), 
7.78 (s, 1H, C-H thiazole), 7.84 (d, 2H, J = 8 Hz, C2-
H, C6-H phenyl); MS (m/z, %): 287 (5), 286 (15), 265 
(20), 202 (65), 174 (20), 149 (25), 116 (40), 91 (82), 
89 (100), 85 (40), 54 (22). Elem. anal. for 
C16H18N2OS: Calc. C: 67.10, H: 6.33, N: 9.78; found 
C: 66.97, H: 6.28, N: 9.83. 
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Docking Studies 
Docking studies were done using ArgusLab 4.0 soft-
ware.12 All ligands were drawn and energy minimiza-
tion was performed for all of them by AM1 
semiemperical method. The related pdb files of c-Src 
and erb protein tyrosine kinases were downloaded from 
protein databank with 3G5D and 3BBT pdb code re-
spectively.13 The geometry optimization of protein 
structures were performed using UFF molecular me-
chanic force field. The docking process was done for all 
ligands in the workspace of ArgusLab software after 
defining the related groups for each ligand and also for 
protein. The binding location of lapatinib and dasatinib 
in the crystal structure of each tyrosine kinase enzyme 
was assumed as the reference binding location for find-
ing the best pose and conformation for all ligands. The 
grid box for docking of each ligand was considered and 
its size was calculated by ArgusLab software automati-
cally. A grid resolution 0.4 Å was assigned and maxi-
mum number of poses was defined 150 poses. Ascore 
was used as scoring function in this process. ArgusDock 
was applied as docking engine. Docking process run 
according to the flexible ligand docking for all intended 
ligands and regular precision was applied for docking 
precision. Binding free energies were acquired and 
listed in Table 1. Binding mode and related interactions 
of ligands were explored in Molegro molecular viewer 
software.14 
Cytotoxicity Assay 
Compounds 3−7 were tested against T47D cells as 
breast cancer cell line according to the literature.15 The 
MTT assay were used for obtaining IC50 (µg/mL) in the 
presence of doxorubicin as reference drug. 
 
RESULTS AND DISCUSSION 
Chemistry 
All compounds were synthesized according to the 
Scheme 1 with acceptable yields (Table 2). p-
toluonitrile was used to commence the synthesis pro-
cess. The conversion of nitrile group to thioamide de-
rivative was done using ammonium disulfide. Thiazole 
ring closure was carried out by dichloroacetone and acid 
hydrolysis of obtained chloromethyl derivative led to 
the related alcohol derivative. Two continuous oxidative 
reactions were afforded the carboxylic derivative by 
passing from an aldehyde intermediate. Intermediate 
and final compounds were purified by crystallization or 
column chromatography and were characterized by 
NMR, IR and Mass spectroscopy and also elemental 
analysis was reported for all synthesized compound. 
 
Cytotoxicity Assay 
MTT assay was done for compounds 3−7 and the results 
of cytotoxicity assay were listed as IC50 (µg/mL) in 





Binding free energy(kcal/mol) 
c-Src tyrosine kinase 
Binding free energy(kcal/mol) 
erb tyrosine kinase 
3 -CH2Cl     5 −9.13   −9.83 
4 -CH2OH        2.5 −9.34 −10.18 
5 -CHO >10 −9.02   −9.01 
6 -COOH >10 −9.08   −9.85 
7 -CO-piperidine     5 −9.57   −9.79 
 Doxorubicin        2.5 - - 
 
Table 2. The properties related to the compounds 2−7 
 
Closed Formula Molecular Weight (g/mol) Yield / % Melting point / °C 
2 C8H9NS 151 92 160 
3 C11H10ClNS 223 88 129 
4 C11H11NOS 205 75 114–115 
5 C11H9NOS 203 70 128–130 
6 C11H9NO2S 219 82 123 
7 C16H18N2OS 286 70 78 
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Table 1. The potencies of all compound were compared 
with doxorubicin in T47D cell line. Compound 4 with 
hydroxymethyl moiety was the best in this series with 
equal IC50 in comparison with doxorubicin. Compound 5 
and 6 showed lower potency than reference drug with 
formyl and carboxylate substitutions respectively. Chloro-
methyl substitution in compound 3 as well as piperidinyl-
carbonyl substitution in compound 7 afforded two com-
pounds with lower potency than doxorubicin. Although 
compounds 3 and 7 were weaker than reference drug, but 
both of them have acceptable inhibitory concentration in 
this series and also in comparison with doxorubicin. 
Figure 2. 3D view of compound 4 after molecular docking into the active site of c-Src tyrosine kinase (PDB code: 3G5D). Ligand
is rendered in stick and amino acid residues of protein in frame. Three hydrogen bindings between hydroxyl residue of compound
4 and Ileu 336 (2.34 Å), Lys 295 (2.76 Å) and Ala 293 (3.60 Å) are visible and have been represented in green dashed. 
 
Figure 3. 3D view of superimposed structure of compound 4 with dasatinib. A good overlaid of phenyl ring of the compound 4 
with thiazole ring of the dasatinib is observed. 
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Molecular Docking 
All ligands (compound 3−7) were docked into the active 
site of c-Src tyrosine kinase as well as erb tyrosine kinase 
for obtaining the likely interactions. This two types of 
tyrosine kinases have pivotal role in pathology of breast 
cancer. Docking studies of ligands were revealed the 
probable interactions between the ligands and both of c-
Src and erb tyrosine kinases. Molecular docking of com-
pound 7 with piperidinylcarbonyl moiety into the active 
site of c-Src tyrosine kinase showed the highest binding 
free energy in comparison with other agents in the series. 
Compound 5 with a formyl group was the weakest agent 
for inhibition of c-Src tyrosine kinase. Compound 4 with 
hydroxymethyl substitution was obtained the second rank 
of calculated enzyme inhibition and a hydrogen binding 
interaction was showed in the most stable conformation 
of this ligand in the active site of c-Src tyrosine kinase. 
Three hydrogen bindings between hydroxyl residue of 
compound 4 and Ileu 336 (2.34 Å), Lys 295 (2.76 Å) and 
Ala 293 (3.60 Å) were detected (Figure 2). A superim-
posed conformation of compound 4 with dasatinib was 
also prepared (Figure 3). According to this figure, the 
phenyl ring of compound 4 occupied a similar location in 
the active site of Src kinase like thiazole ring of dasatinib. 
According to the Table 1, molecular docking of 
ligands 3−7 into the active site of erb tyrosine kinase 
showed the highest binding free energy for compound 4 
(−10.18 Kcal/mol) and a very important hydrogen bind-
ing were detected between the hydroxyl moiety of com-
pound 4 and Asp 1121 in the active site of erb tyrosine 
kinase (Figure 4). 
 
CONCLUSION 
A new series of phenylthiazole analogs were synthe-
sized and their anticancer activity was evaluated in 
vitro. According to the obtained data from molecular 
modeling and cytotoxicity evaluation, it could be con-
cluded that 4-Substituted-2-p-tolylthiazole derivatives 
have acceptable in silico inhibition of c-Src and erb 
tyrosine kinases in neoplastic cells. Cytotoxicity as-
sessment against T47D breast cancer cell line ap-
proved the in vitro efficacy of these compounds. Com-
pound 4 with an alcoholic (Hydroxymethyl) moiety 
was the best compound in this series (IC50 = 2.5 
 
Figure 5. Structure of compound 4 with hydroxyl substituent
as potential anticancer lead compound (IC50 = 2.5 µg/mL). 
 
Figure 4. 3D view of compound 4 after molecular docking into the active site of erb tyrosine kinase (PDB code: 3BBT). Ligand is
rendered in stick and amino acid residues of protein in ball-stick. Hydrogen binding between hydroxyl residue of compound 4 and
Asp 1121 is visible and has been represented in green dashed. The hydrogen binding distance between the hydroxyl group and
Asp amino acid is 2.41 Å. 
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µg/mL). Hydrogen binding interactions of compound 4 
via hydroxyl substituent enhances its activity com-
pared to other synthesized derivatives in this series. 
Finally, we conclude that compound 4 can be proposed 
as potential anticancer lead compound (Figure 5). But, 
further experimental tests are necessary to prove this 
statement. 
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